DEPLOYDatabase

Person

Dr. Yvonne Linney

Chief Operating Officer of Artificial Inc., a lab automation company providing a first-of-its-kind orchestration platform for life science labs. Joined Artificial in January 2021, bringing 30+ years of executive experience at industry-leading life sciences and diagnostic companies. Previously COO and then CEO of Transcriptic (now Strateos), where she brokered a multi-year, multi-million dollar agreement with Eli Lilly.

Before that, VP and GM of the Life Science Solutions Division at Agilent Technologies, where she established a $1.5B Life Science Group. Also held senior roles at Bayer Diagnostics (now Siemens Healthcare), Caliper Life Sciences, and Amersham International (now GE Healthcare). Serves on the board of Bionano Genomics. Holds a BS in Microbiology and Virology from Warwick University and a PhD in Genetics from Leicester University, UK.

British · 1 current role

Track Dr. Yvonne Linney

Physical AI footprint (1)

The physical AI companies Dr. is connected to that DEPLOY verifies. The full record is one click away.

Current roles (1)

Sources (3)

  1. https://www.businesswire.com/news/home/20210119005125/en/Artificial-Inc.-Expands-Leadership-Team-and-Board-of-Directors-to-Catalyze-the-Labs-Digital-Revolution
  2. https://ir.bionanogenomics.com/static-files/e7088a54-dafe-4471-8cb0-e6d557089e99
  3. https://www.citybiz.co/article/365730/sengenics-appoints-yvonne-linney-phd-as-board-director/

Deploy Watch

Track Dr. Yvonne Linney on Deploy.

We notify you when a verified role changes, a founded-company event lands, or litigation surfaces.